Safety of 6′-sialyllactose (6′-SL) sodium salt produced by
derivative strains of Escherichia coli BL21 (DE3) as a novel
food pursuant to Regulation (EU) 2015/2283

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA),
Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw,
Karen Ildico Hirsch-Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies,
Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen,
Rosangela Marchelli, Monika Neuhäuser-Berthold, Morten Poulsen, Miguel Prieto Maradona,
Josef Rudolf Schlatter, Henk van Loveren, Paolo Colombo, Estefania Noriega Fernández and
Helle Katrine Knutsen

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on 6′-sialyllactose (6′-SL) sodium salt as a novel
food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical
milk oligosaccharide (HiMO) 6′-SL, but it also contains δ-lactose, 6′-sialyllactulose, sialic acid, N-acetyl-δ-
glucosamine and a small fraction of other related oligosaccharides. The NF is produced by fermentation
with two genetically modified strains of Escherichia coli BL21 (DE3), the production strain and the
optional degradation strain. The information provided on the identity, manufacturing process,
composition and specifications of the NF does not raise safety concerns. The applicant intends to add the
NF to a variety of foods, including infant formula and follow-on formula, food for special medical
purposes and food supplements. The target population is the general population. In some scenarios at
the maximum use levels, the estimated intakes per kg body weight were higher than the high average
natural intake of 6′-SL from human milk. However, given the intrinsic nature of human milk
oligosaccharides (HMOs), the wide range of intakes from human milk, and considering that infants are
naturally exposed to similar amounts of these substances, the Panel considers that the consumption of
the NF at the proposed conditions of use does not raise safety concerns. The intake of 6′-SL in breastfed
infants on a body weight basis is also expected to be safe for other population groups. The intake of
other carbohydrate-type compounds structurally related to 6′-SL is also considered of no safety concern.
Food supplements are not intended to be used if other foods with added 6′-SL or human milk are
consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of
use.

© 2022 Wiley-VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

Keywords: 6′-sialyllactose, 6′-SL sodium salt, human milk oligosaccharide, HMO, HiMO, novel food,
safety

Requestor: European Commission

Question number: EFSA-Q-2020-00623

Correspondence: nif@efsaeuropa.eu
Panel members: Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri and Marco Vinceti

Declarations of interest: If you wish to access the declaration of interests of any expert contributing to an EFSA scientific assessment, please contact interestmanagement@efsaeuropa.eu.

Suggested citation: EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Colombo P, Noriega Fernández E and Knutsen HK, 2022. Scientific Opinion on the safety of 6′-sialyllactose (6′-SL) sodium salt produced by derivative strains of Escherichia coli BL21 (DE3) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2022;20(12):7645, 29 pp. https://doi.org/10.2903/j.efsa.2022.7645

ISSN: 1831-4732

© 2022 Wiley-VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, a European agency funded by the European Union.
Table of contents

Abstract .................................................................................................................................................. 1
1. Introduction ................................................................................................................................... 4
1.1. Background and terms of reference as provided by the requestor .................................................. 4
1.2. Additional information ................................................................................................................. 4
2. Data and methodologies .................................................................................................................. 4
2.1. Data ............................................................................................................................................. 4
2.2. Methodologies ............................................................................................................................ 5
3. Assessment ................................................................................................................................... 5
3.1. Introduction ................................................................................................................................. 5
3.2. Identity of the NF ....................................................................................................................... 6
3.3. Production process ..................................................................................................................... 7
3.4. Compositional data .................................................................................................................... 8
3.4.1. Stability .................................................................................................................................... 11
3.5. Specifications ............................................................................................................................. 11
3.6. History of use of the NF and/or of its source .............................................................................. 12
3.6.1. History of use of the NF ......................................................................................................... 12
3.6.2. Intake of 6'-SL from human milk ............................................................................................ 13
3.7. Proposed uses and use levels and anticipated intake ................................................................... 14
3.7.1. Target population .................................................................................................................. 14
3.7.2. Proposed uses and use levels .................................................................................................. 14
3.7.3. Anticipated intake of the NF .................................................................................................. 14
3.7.4. Anticipated intake of the NF from food supplements ................................................................. 15
3.7.5. Combined intake from the NF and other sources .................................................................... 16
3.8. Absorption, distribution, metabolism and excretion (ADME) ....................................................... 17
3.9. Nutritional information ............................................................................................................. 17
3.10. Toxicological information ......................................................................................................... 17
3.10.1. Genotoxicity ....................................................................................................................... 18
3.10.2. Subchronic toxicity .............................................................................................................. 19
3.10.3. Human data ......................................................................................................................... 20
3.11. Allergenicity ............................................................................................................................. 20
4. Discussion .................................................................................................................................... 21
5. Conclusions .................................................................................................................................. 22
6. Steps taken by EFSA ...................................................................................................................... 22
References .......................................................................................................................................... 22
Abbreviations ..................................................................................................................................... 26
Appendix A – Authorised and proposed uses and use levels for 6'-SL .................................................. 28
Annex A – Dietary exposure estimates to the Novel Food for each population group from each EU dietary survey .................................................................................................................. 29
1. Introduction

1.1. Background and terms of reference as provided by the requestor

On 15 May 2020, the company Chr. Hansen A/S submitted a request to the Commission in accordance with Article 10 of Regulation (EU) No 2015/2283\(^1\) to place on the EU market 6′-sialyllactose (6′-SL) sodium salt as a novel food (NF).

6′-SL sodium salt is intended to be used in a number of food categories.

In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission (EC) asks the European Food Safety Authority (EFSA) to provide a scientific opinion on the safety of 6′-SL sodium salt as a NF.

In addition, EFSA is requested to include in its scientific opinion a statement as to if, and if so to what extent, the proprietary data for which the applicant is requesting data protection was used in elaborating the opinion in line with the requirements of Article 26(2)(c) of Regulation (EU) 2015/2283.

1.2. Additional information

Sodium salts of 6′-SL and its constitutional isomer 3′-sialyllactose (3′-SL) are included in the EU Union list of authorised NFs (Commission Implementing Regulation (EU) 2017/2470\(^2\)) when produced by fermentation with genetically modified strains of *Escherichia coli* K-12 DH1 (EFSA NDA Panel, 2020a,b). Moreover, the safety of the 3′-SL sodium salt produced with derivative strains of *E. coli* BL21 (DE3) has recently been assessed by EFSA with a positive outcome (EFSA NDA Panel, 2022a).

Since 2015, several scientific opinions have been adopted by the EFSA NDA Panel on the safety of human-identical milk oligosaccharides (HiMOs) as NFs pursuant to Regulation (EC) No 258/97 or Regulation (EU) 2015/2283:

- Chemically synthetised 2′-fucosyllactose (2′-FL) (EFSA NDA Panel, 2015a);
- Chemically synthetised lacto-N-neotetraose (LNnT) (EFSA NDA Panel, 2015b) and LNnT produced with derivative strains of *E. coli* BL21 (DE3) (EFSA NDA Panel, 2020c);
- Extension of use in food supplements (FS) for infants of chemically synthetised 2′-FL and LNnT (EFSA NDA Panel, 2015c) or 2′-FL and LNnT produced with derivative strains of *E. coli* K-12 DH1 (EFSA NDA Panel, 2022b);
- Chemically synthetised N-acetyl-D-neuraminic acid (NANA) (EFSA NDA Panel, 2017);
- 2′-FL/difucosyllactose (DFL) mixture produced with a derivative strain of *E. coli* K-12 DH1 (EFSA NDA Panel, 2019a);
- Lacto-N-tetraose (LNT) produced with a derivative strain of *E. coli* K-12 DH1 (EFSA NDA Panel, 2019b) or with derivative strains of *E. coli* BL21 (DE3) (EFSA NDA Panel, 2022c);
- Extension of use in FS for infants of 2′-FL/DFL mixture and LNT produced with derivative strains of *E. coli* K-12 DH1 (EFSA NDA Panel, 2022d);
- 6′-SL sodium salt produced with a derivative strain of *E. coli* K-12 DH1 (EFSA NDA Panel, 2020a);
- 3′-SL sodium salt produced with a derivative strain of *E. coli* K-12 DH1 (EFSA NDA Panel, 2020b) or with derivative strains of *E. coli* BL21 (DE3) (EFSA NDA Panel, 2022a);
- 3-fucosyllactose (3-FL) produced with a derivative strain of *E. coli* K-12 MG1655 (EFSA NDA Panel, 2021) or with a derivative strain of *E. coli* BL21 (DE3) (EFSA NDA Panel, 2022e).

2. Data and methodologies

2.1. Data

The safety assessment of this NF is based on data supplied in the application, information submitted by the applicant following an EFSA request for supplementary information and additional data identified by the Panel.

---

\(^1\) Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. OJ L 327, 11.12.2015, pp. 1-22.

\(^2\) Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351, 30.12.2017, pp. 72-201.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation (EU) 2015/2283 are listed in Commission Implementing Regulation (EU) 2017/2469\(^3\).

A common and structured format on the presentation of NF applications is described in the EFSA guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016). As indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary, confidential and published) scientific data (both in favour and not in favour) that are pertinent to the safety of the NF.

This NF application includes a request for protection of proprietary data in accordance with Article 26 of Regulation (EU) 2015/2283. The data requested by the applicant to be protected comprise: (i) identity of the NF; (ii) toxicological information; (iii) information on the genetically modified production strain and the genetically modified optional degradation strain; (iv) method validation reports for the determination of the carbohydrate content in the NF.

### 2.2. Methodologies

The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and in Article 7 of Commission Implementing Regulation (EU) 2017/2469. The legal provisions for the assessment of food intended for infants and young children and food for special medical purposes (FSMP) are laid down in Regulation (EU) No 609/2013\(^4\) and, respectively, in Commission Delegated Regulation (EU) 2016/1276\(^4\) (FSMP), and in Commission Delegated Regulation (EU) 2016/1278\(^5\) (as regards the specific compositional and information requirements for infant formula (IF) and follow-on formula (FOF) and as regards requirements on information relating to infant and young child feeding).

This assessment concerns only the risks that might be associated with the consumption of the NF under the proposed conditions of use and is not an assessment of the efficacy of the NF with regard to any claimed benefit. Furthermore, this assessment also is not an assessment on whether the NF is suitable as stipulated by Regulation (EU) No 609/2013.

### 3. Assessment

#### 3.1. Introduction

The NF’s primary constituent is the sodium salt of 6′-SL, henceforth named ‘6′-SL sodium salt’ (≥ 90.0% w/w dry matter (DM)). 6′-SL has been identified as a relevant component of the complex fraction of oligosaccharides naturally occurring in human milk, also acknowledged as human milk oligosaccharides (HMOs). 6′-SL is a sialylated (acidic) trisaccharide composed of D-glucose, D-galactose and NANA (hereinafter also referred to as ‘sialic acid’). 6′-SL is the predominant acidic HMO and one of the most abundant HMOs along with 2′-FL, lacto-N-fucopentaose I, LNT and LNnT (Thurl et al., 2010, 2017). The Panel notes that although the 6′-SL sodium salt is the major component of the NF, related substances, namely α-lactose, 6′-sialyllactulose, sialic acid, N-acetyl-D-glucosamine and a small fraction of other related saccharides, are also present. The NF is produced by fermentation with two derivative strains of E. coli BL21 (DE3), the production strain and the optional degradation strain, and is isolated as a purified ingredient in the sodium salt form.

---

\(^3\) Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.

\(^4\) Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive 92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181, 29.6.2013, pp. 35–56.

\(^5\) Commission Delegated Regulation (EU) 2016/128 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council as regards the specific compositional and information requirements for food for special medical purposes. OJ L 25, 2.2.2016, pp. 30–43.
The NF is proposed to be used in IF, FOF, processed cereal-based food, baby food and FSMP as defined in Regulation (EU) No 609/2013, and FS as defined in Directive 2002/46/EC. The target population is the general population.

Sodium salts of 6'-SL (EFSA NDA Panel, 2020a) and 3'-SL (EFSA NDA Panel, 2020b), produced with derivative strains of *E. coli* K-12 DH1, have been previously assessed by EFSA and authorised as NFs. In addition, 2'-FL and LNNt (EFSA NDA Panel, 2020c), produced with derivative strains of the same host strain *E. coli* BL21 (DE3), have been authorised as NFs in the European Union (Commission Implementing Regulation 2017/2470), and LNT, 3'-SL sodium salt and 3-FL produced with derivative strains of *E. coli* BL21 (DE3) have recently been assessed by EFSA with positive outcomes (EFSA NDA Panel, 2022a,c,e).

According to Article 3(2)(a) of Regulation (EU) No 2015/2283, the NF falls under the following categories:

i) 'food with a new or intentionally modified molecular structure, where that structure was not used as, or in, a food within the Union before 15 May 1997'; and

ii) 'food consisting of, isolated from or produced from microorganisms, fungi or algae'.

### 3.2. Identity of the NF

The NF is a powdered mixture mainly composed of 6'-SL sodium salt (≥ 90.0% w/w DM), but it also contains d-lactose (≤ 5.0% w/w DM), 6'-sialyllactose (≤ 3.0% w/w DM), sialic acid (≤ 2.0% w/w DM), N-acetyl-D-glucosamine (≤ 3.0% w/w DM) and a small fraction of other saccharides (sum of other carbohydrates ≤ 5.0% w/w DM). It is produced by fermentation with two genetically modified strains of *E. coli* BL21 (DE3), the production strain and the optional degradation strain. The main component is the sodium salt of Neu5Ac-α-(2-6)-Gal-β-(1-4)-Glc (6'-SL) in which sodium N-acetyl-D-neuraminate is linked through an α-(2-6) bond to β-galactose which is linked through a β-(1-4) bond to β-glucose, in its α- and β-anomeric forms (Table 1; Figure 1). 6'-SL is a regioisomer of 3'-SL, which contains the same monosaccharide moieties as those present in 6'-SL but with the linkage between N-acetyl-D-neuraminic acid (Neu5Ac) and β-galactose being α-(2-3) rather than α-(2-6).

### Table 1: Chemical identity of 6'-SL sodium salt

| Chemical substance | Chemical (IUPAC) name | Common name | Abbreviations | Alternative chemical names |
|--------------------|-----------------------|-------------|---------------|---------------------------|
|                    | N-Acetyl-α-Neuraminyl-(2→6)-β-β-galactopyranosyl-(1→4)-β-glucopyranose, sodium salt | 6'-Sialyllactose, sodium salt | 6'-SL, sodium salt | 6'-SL sodium salt |
|                    | 6'-N-acetylneuraminyl-β-lactose sodium salt | α-Neu5Ac-(2→6)-β-β-Gal-(1→4)-β-Glc sodium salt |
| CAS Number         | 157574-76-0 (sodium salt)/35890-39-2 (acid) |
| Molecular formula  | C23H38NO19Na |
| Molecular weight   | 655.53 Da |

The molecular structure of 6'-SL has been determined by high-performance liquid chromatography – electrospray ionisation – tandem mass spectrometry (HPLC-ESI-MS/MS), based on its collision induced dissociation (CID) fragmentation pattern and multiple reaction monitoring (MRM) analysis, by comparison with a high purity in-house standard and a high purity commercially available standard.

The identity of 6'-SL was also confirmed by high-performance anion-exchange chromatography – pulsed amperometric detection (HPAEC-PAD) by comparison with a high purity in-house standard.

The structure of 6'-SL has been confirmed by mono-dimensional (1D) NMR spectroscopy including 1H, 13C and 13C-DEPT-90 (distortionless enhancement by polarisation transfer) spectra, and two-dimensional (2D) NMR spectroscopy, including 1H-1H-COSY (correlated spectroscopy), 1H-13C-HSQC (heteronuclear single quantum correlation), 1H-13C-HMBC (heteronuclear multiple-bond correlation) and 1H-13C HSQC-TOCSY (heteronuclear single quantum correlation total correlation spectroscopy) spectra. All correlations for carbons involved in glycosidic bonds were evidenced in the HSQC spectrum

---

7 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. OJ L 183, 12.7.2002, pp. 51–57.
and the inter-glycosidic correlations showing the inter-residue interactions were confirmed by the HMBC spectrum. Taken together, NMR data confirm that the glycosidic linkage between Neu5Ac C-2 and the adjacent β-galactose (Gal) H-6′ is α-(2-6). An inter-residual correlation was also observed between Gal H-1′ and D-glucose (Glc) C-4 in the HMBC spectrum. This, together with the coupling constants of the Gal H-1′ and the Glc H-1 signals, indicates that: (i) the link between the Gal and the Glc units is β-(1-4); (ii) the pyranose configuration is β for the Gal unit; and (iii) the terminal D-glucose in water solution is in equilibrium between the α- and the β-anomeric forms.

Figure 1: Chemical structure of 6′-SL sodium salt (EFSA NDA Panel, 2020a)

The 6′-SL produced by the microbial fermentation described has been shown to be chemically and structurally identical to authentic standards by HPLC-ESI-MS/MS, HPAEC-PAD, and 1D and 2D NMR spectroscopy, and the Panel considers it as being a HiMO.

3.3. Production process

According to the information provided by the applicant, the NF is produced in line with Good Manufacturing Practice (GMP) and Hazard Analysis Critical Control Points (HACCP) principles, in a facility that is ISO:9001 and FSSC (Food Safety System Certification) 22000 certified.

The NF is produced by a two-step fed-batch fermentation process using two genetically modified strains derived from the host strain *E. coli* BL21 (DE3). These strains are the production strain *E. coli* BL21 (DE3) PS-6′-SL-JBT and the optional degradation strain *E. coli* BL21 (DE3) DS-6′-SL-JBT. The production strain has been modified to effectively synthesise 6′-SL, while the degradation strain is equipped with enzymes to degrade intermediate carbohydrate by-products and remaining substrates in order to facilitate the production process. Glycerol, glucose, and/or sucrose can be used as carbon sources for the cultivation of both strains and lactose is utilised as a substrate for the production of 6′-SL by the production strain. The process is carried out without inhibitors, inducers or antibiotics and no solvents are used except water. The duration of the fermentation step is set to optimise the concentration of 6′-SL. At the end of the fermentation process, the bacterial biomass is removed from the final product by centrifugation and ultrafiltration. The isolation, purification and concentration of the product involves several filtration, ion removal and decolourisation steps. All chemicals used in the process are of food-grade quality. Other processing aids, such as ion exchange resins, activated carbon and filtration membranes, are also in conformance with the manufacture of food. The concentrated purified 6′-SL sodium salt is spray-dried to obtain a powder form.

The production strain and the optional degradation strain, *E. coli* BL21 (DE3) PS-6′-SL-JBT and *E. coli* BL21 (DE3) DS-6′-SL-JBT respectively, are genetically modified derivatives of the host strain *E. coli* BL21 (DE3) (F ompT hsdS B (rB mB) gal dcm (DE3)). The *E. coli* BL21 (DE3) strain was developed through T7 RNA polymerase-based gene expression by introducing a lambda prophage containing a T7 RNA polymerase under the control of lacUVA promoter and it is typically used in laboratories worldwide. *E. coli* BL21 (DE3) is considered to be non-pathogenic and unlikely to survive in host tissues or to cause disease (Chart et al., 2000). The genome sequence of *E. coli* BL21 (DE3) showed the absence of genes encoding invasion factors, adhesion molecules and enterotoxins associated with virulence (Jeong et al., 2009). Both the production and the optional degradation
strains have been deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ). A detailed description of the genetic modification steps applied to obtain both the production and the optional degradation strains has been provided by the applicant. No residual DNA from the production or the optional degradation strains was detected in the NF using quantitative polymerase chain reaction (qPCR) amplification of (a) four antimicrobial resistance genes introduced during the genetic modification of the production strain and (b) a specific DNA sequence for the optional degradation strain. The absence of both DNA and viable cells from the production and the optional degradation strains has been demonstrated in accordance with the EFSA Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018).

The Panel considers that the production process is sufficiently described and does not raise safety concerns.

3.4. Compositional data

Batch-to-batch analyses showed that the NF consists of 6′-SL sodium salt as primary ingredient (95.0% w/w DM as sodium salt). The remainder is a mixture of substances\(^8,9\) such as α-lactose (< 0.2% w/w DM), 6′-sialyllactulose (< 0.9% w/w DM), sialic acid (< 0.1% w/w DM) and N-acetyl-α-glucosamine (< 0.1% w/w DM). In addition, the NF contains other carbohydrates individually present at low concentration (sum of other carbohydrates, 0.4% w/w DM\(^8,9,10\)).

With regards to the physicochemical properties, the NF can be described as a white to ivory-coloured powder. It is readily soluble in aqueous solutions (min. 500 g/L in water at ambient temperature).

In order to confirm that the manufacturing process is reproducible and adequate to produce on a commercial scale a product with certain required characteristics, the applicant provided analytical information for 10 batches of the NF (Table 2). Information was provided on the accreditation of the laboratories that conducted the analyses presented in the application.

---

\(^8\) Average content in 10 batches of the NF.

\(^9\) For those batches of the NF where the levels of any carbohydrate by-product were below the respective limit of quantification (LOQ), the concentration of the corresponding compound has been considered to be equal to the respective LOQ value for the purpose of calculating its average content in the 10 batches of the NF, and the sum of other carbohydrates in the corresponding batch.

\(^10\) Sum of other carbohydrates = 100 (% w/w DM) – 6′-SL sodium salt (% w/w DM) – Quantified carbohydrates (% w/w DM) – Ash (% w/w DM).
Table 2:  Batch to batch analysis of the NF

| Parameters                          | Batches | Methods                                      |
|-------------------------------------|---------|----------------------------------------------|
|                                     | #1      | #2                                           |
| Composition                         |         |                                              |
| 6'-SL sodium salt (% w/w DM)        | 96.2    | 94.3                                         |
| o-Lactose (% w/w DM)                | < LOQ   | < LOQ                                        |
| Sialic acid (% w/w DM)              | < LOQ   | < LOQ                                        |
| N-acetyl-o-glucosamine (% w/w DM)   | < LOQ   | < LOQ                                        |
| 6'-Sialyllactulose (% w/w DM)       | –       | –                                            |
| Sum of other carbohydrates (% w/w DM)| 0.0     | 1.5                                          |
| Protein (%)                         | 0.002   | 0.002                                        |
| Ash (%)                             | 5.7     | 3.8                                          |
| Water (%)                           | 7.7     | 7.8                                          |
| Sodium (%)                          | 3.0     | 3.1                                          |
| Contaminants                        |         |                                              |
| Arsenic³ (mg/kg)                    | < LOQ   | < LOQ                                        |
| Cadmium³ (mg/kg)                    | < LOQ   | < LOQ                                        |
| Lead³ (mg/kg)                       | < LOQ   | < LOQ                                        |
| Mercury³ (mg/kg)                    | < LOQ   | < LOQ                                        |
| Aflatoxin M1 (µg/kg)                | < 0.025 | < 0.025                                      |
| Microbial parameters                |         |                                              |
| Standard plate count (CFU/g)        | < 10    | < 10                                         |
| Yeast (CFU/g)                       | < 10    | < 10                                         |
| Mould (CFU/g)                       | < 10    | < 10                                         |
| Enterobacteriaceae (CFU/g)          | < 10    | < 10                                         |
| Salmonella spp. (in 25 g)           | ND      | ND                                           |
| Cronobacter spp. (in 10 g)          | ND      | ND                                           |
| Listeria monocytogenes (in 25 g)    | ND      | ND                                           |

1 HPAEC-PAD (validated internal method)
2 Calculation
3 Microbial parameters

Safety of 6'-sialyllactose sodium salt
### Parameters

| Parameters                  | #1  | #2  | #3  | #4  | #5  | #6  | #7  | #8  | #9  | #10 |
|-----------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| *Bacillus cereus* (in 5 g) | ND  | ND  | –   | ND  | ND  | –   | –   | –   | –   | –   |
| Endotoxins (EU/mg)          | 0.034 | 0.014 | 0.034 | 0.016 | 0.009 | < 0.005 | < 0.005 | < 0.005 | < 0.005 | < 0.005 |

### Methods

| Methods |
|---------|
| ASU L 00.00-108: 2007-04 |

1."- Not reported; 6'-SL: 6'-Sialyllactose; ASU: Official collection of analysis methods according to § 64 of the German Food and Feed Code (LFGB); CFU: Colony forming unit; DIN: German Institute for Standardisation e. V.; DM: Dry matter; EN: European norm; EU: Endotoxin unit; HPAEC-PAD: High-performance anion-exchange chromatography – pulsed amperometric detection; IAC-HPLC-FD: Immunoaffinity chromatography – high-performance liquid chromatography – fluorescence detector; ICP-MS: Inductively coupled plasma – mass spectrometry; ISO: International Organisation for Standardisation; LOQ: Limit of quantification; ND: Not detected; Ph. Eur.: European Pharmacopeia; TS: Technical specification.

(1): LOQs: d-Lactose = 0.14% w/w DM; Sialic acid = 0.14% w/w DM; N-acetyl-D-glucosamine = 0.14% w/w DM; 6'-Sialyllactulose = 0.90% w/w DM.

(2): Sum of other carbohydrates = 100 (% w/w DM) – 6'-SL sodium salt (% w/w DM) – Quantified carbohydrates (% w/w DM) – Ash (% w/w DM). For those batches of the NF where the levels of any carbohydrate by-product were below the respective limit of quantification (LOQ), the concentration of the corresponding compound has been considered to be equal to the respective LOQ value for the purpose of calculating the sum of other carbohydrates in the corresponding batch.

(3): LOQs: Arsenic = 0.05 mg/kg; Cadmium = 0.010 mg/kg; Lead = 0.010 mg/kg; Mercury = 0.005 mg/kg.
The Panel considers that the information provided on the composition of the NF is sufficient and does not raise safety concerns.

3.4.1. Stability

**Stability of the NF**

The applicant performed stability tests on one batch of a HiMO mixture containing 2'-FL (47.7% w/w DM), 3-FL (15.1% w/w DM), LNT (24.7% w/w DM), 3'-SL sodium salt (4.3% w/w DM), 6'-SL sodium salt (5.6% w/w DM) and other carbohydrates (5.7% w/w DM). The applicant stated that the 6'-SL sodium salt included in the HiMO mixture was manufactured according to the production process described in Section 3.3. The Panel considers that the presence of other HiMOs is not expected to affect the stability of 6'-SL. The tests were carried out at normal (25°C and 60% relative humidity (RH)) and accelerated (40°C and 75% RH) storage conditions for a period of 104 and 26 weeks, respectively. The samples were analysed for 6'-SL (HPAEC-PAD) and moisture (Karl-Fischer titration) content. Upon EFSA's request for additional information, the applicant provided stability data up to 156-week storage under normal conditions, also reporting the concentration of the individual carbohydrates present in the HiMO mixture throughout the storage period.

The content of 6'-SL (expressed on a DM basis) remained stable over the 156-week period under normal storage conditions (average content of 5.8 ± 0.4% w/w DM), with an increase in the moisture content from 5.7% to 10.9%, which exceeds the specifications (≤ 9.0%). Over the 26-week storage under accelerated conditions, the content of 6'-SL (expressed on a DM basis) remained unchanged (average content of 5.6 ± 0.4% w/w DM), and an increase from 5.7% to 9.9%, again above the specifications, was observed for the moisture content. Under both normal and accelerated conditions, the total concentration and composition of the HiMO mixture (expressed on a DM basis) remained constant.

The applicant was also requested to provide microbiological analysis, in light of the increase in the moisture content throughout the storage period. Thus, three batches of the NF and three batches of the above-mentioned HiMO mixture stored under warehouse conditions for 25 months were analysed for total viable counts, yeasts and moulds. Microbial levels were below the respective limits of detection, and the moisture content was within the specifications (average content of 8.1 ± 0.2% in the NF and 6.6 ± 1.2% in the HiMO mixture).

The applicant also referred to the stability studies included in the GRAS (Generally Recognised As Safe) notifications GRN (GRAS Notice) 766, GRN 880 and GRN 881 (USFDA, 2019, 2020a,b) on 3'-SL and 6'-SL sodium salts produced by enzymatic synthesis or fermentation with a derivative strain of *E. coli* K-12 DH1, as well as to the stability of the authorised NF for at least 24 months when stored at room temperature (EFSA NDA Panel, 2020a). The applicant proposed a 1-year shelf-life from the date of production of the NF, when stored under ambient conditions.

The Panel considers that the data provided sufficient information with respect to the proposed stability of the NF for 1 year.

**Stability of the NF under the intended conditions of use**

A stability study was conducted with two batches of powdered IF and three batches of a ready-to-use liquid IF using the above-mentioned HiMO mixture, which contains the NF. The concentration of the individual HiMOs (HPAEC-PAD) and pH levels were determined immediately after production and after 3- and 6-month storage at ambient conditions. The content of 6'-SL sodium salt remained constant over the storage period and its stability in IF was demonstrated up to 6 months at ambient conditions.

No stability data for 6'-SL sodium salt in other food matrices were provided. The NDA Panel concluded in its previous assessment of this HiMO that 'the available data provide sufficient information with respect to the stability of the NF in the food matrices at neutral pH, when stored at room temperature under proper storage conditions' (EFSA NDA Panel, 2020a).

The Panel considers that the information already available is sufficient with respect to the stability of the NF in the proposed food matrices.

3.5. Specifications

The specifications of the NF are indicated in Table 3.
The Panel considers that the information provided on the specifications of the NF is sufficient and does not raise safety concerns.

3.6. History of use of the NF and/or of its source

3.6.1. History of use of the NF

There is no history of use of the NF. However, 6'-SL, which is the major constituent of the NF, has been authorised as a NF in the EU (Commission Implementing Regulation 2021/9611) to be added to IF and FOF, to a variety of foods as well as to FS. The authorised 6'-SL is obtained by fermentation from the genetically modified *Escherichia coli* K12 DH1.

6'-SL has been also detected in domestic farm animal milk, albeit at lower concentrations as compared to human milk. Oligosaccharides in bovine milk are 20 times less concentrated than in human milk. However, sialylated oligosaccharides accounted for approximately up to 80% of the total oligosaccharide pools. The amount of 6'-SL in bovine milk is estimated to range from 4 to 10 mg/L and up to 100 mg/L in colostrum (Aldredge et al., 2013; Urashima et al., 2013; Albrecht et al., 2014), which is much lower than human milk concentrations (between 0.40 and 0.74 g/L; see Section 3.6.2).

### Table 3: Specifications of the NF

| Parameter                                      | Specification |
|------------------------------------------------|---------------|
| **Composition**                                |               |
| 6'-SL sodium salt (% w/w DM)                   | ≥ 90.0        |
| 6'-Sialyllactulose (% w/w DM)                  | ≤ 3.0         |
| α-Lactose (% w/w DM)                           | ≤ 5.0         |
| Sialic acid (% w/w DM)                         | ≤ 2.0         |
| N-acetylα-D-glucosamine (% w/w DM)             | ≤ 3.0         |
| Sum of other carbohydrates¹ (% w/w DM)         | ≤ 5.0         |
| Water (%)                                      | ≤ 9.0         |
| Protein (%)                                    | ≤ 0.01        |
| Ash (%)                                        | ≤ 8.5         |
| Sodium (%)                                     | ≤ 4.2         |
| **Contaminants**                               |               |
| Arsenic (mg/kg)                                | ≤ 0.2         |
| Aflatoxin M1 (µg/kg)                           | ≤ 0.025       |
| **Microbial parameters**                       |               |
| Standard plate count (CFU/g)                   | ≤ 1,000       |
| Yeast and mould (CFU/g)                        | ≤ 100         |
| Enterobacteriaceae (CFU/g)                     | ≤ 10          |
| *Salmonella* (in 25 g)                         | ND            |
| *Cronobacter* spp. (in 10 g)                   | ND            |
| Endotoxins (EU/mg)                             | ≤ 10          |

6'-SL: 6'-Sialyllactose; CFU: Colony forming unit; DM: Dry matter; EU: Endotoxin unit; ND: Not detected.

(1): Sum of other carbohydrates = 100 (% w/w DM) – 6'-SL sodium salt (% w/w DM) – Quantified carbohydrates (% w/w DM) – Ash (% w/w DM). For those batches of the NF where the levels of any carbohydrate by-product were below the respective limit of quantification (LOQ), the concentration of the corresponding compound has been considered to be equal to the respective LOQ value for the purpose of calculating the sum of other carbohydrates.

The Panel considers that the information provided on the specifications of the NF is sufficient and does not raise safety concerns.

3.6. History of use of the NF and/or of its source

3.6.1. History of use of the NF

There is no history of use of the NF. However, 6'-SL, which is the major constituent of the NF, has been authorised as a NF in the EU (Commission Implementing Regulation 2021/9611) to be added to IF and FOF, to a variety of foods as well as to FS. The authorised 6'-SL is obtained by fermentation from the genetically modified *E. coli* strain K12 DH1.

6'-SL has been also detected in domestic farm animal milk, albeit at lower concentrations as compared to human milk. Oligosaccharides in bovine milk are 20 times less concentrated than in human milk. However, sialylated oligosaccharides accounted for approximately up to 80% of the total oligosaccharide pools. The amount of 6'-SL in bovine milk is estimated to range from 4 to 10 mg/L and up to 100 mg/L in colostrum (Aldredge et al., 2013; Urashima et al., 2013; Albrecht et al., 2014), which is much lower than human milk concentrations (between 0.40 and 0.74 g/L; see Section 3.6.2).

---

11 COMMISSION IMPLEMENTING REGULATION (EU) 2021/82 of 27 January 2021 authorising the placing on the market of 6'-sialyllactose sodium salt as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) 2017/2470, OJ L 29/16.
3.6.2. Intake of 6′-SL from human milk

As reported in previous EFSA opinions (EFSA NDA Panel, 2019b, 2020a,b, 2021), human milk contains a family of structurally related oligosaccharides, known as HMOs, which is the third largest fraction of solid components. The highest concentrations of HMOs occur in human colostrum (20–25 g/L), and concentrations between 5 and 20 g/L occur in mature human milk (Thurl et al., 2010; Bode, 2012; Urashima et al., 2018). Concentration and composition of HMOs vary between mothers and over the course of lactation. 6′-SL is the predominant HMO belonging to the subfraction of ‘acidic’ HMOs, which is characterised by the presence of sialic acids, and the whole subfraction accounts for 1.5–3.3 g/L (Thurl et al., 2010; Rijnierse et al., 2011; Bode, 2012).

There are two naturally occurring sialyllactoses that are constitutional isomers with a minimal structural difference. The oligosaccharide backbone can be sialylated by α-(2-3) or α-(2-6) linkages, resulting in 3′-SL or 6′-SL, respectively. The two forms have been shown to have similar functions and biological roles (Tarr et al., 2015). Several publications on HMOs and 6′-SL in human milk have been provided by the applicant.

The highest concentration of 6′-SL in human milk is reported in colostrum, and as for other HMOs, the concentration is genetically determined and also depends on the stage of lactation (Coppa et al., 1999, 2011; Asakuma et al., 2007; Thurl et al., 2010, 2017; Spevacek et al., 2015; Austin et al., 2016; Kunz et al., 2017; McGuire et al., 2017). Thurl et al. (2017) summarised the findings from 21 studies and reported that the mean concentration of 6′-SL in milk from mothers who delivered at term ranged from 0.38 to 0.91 g/L (average 0.64 g/L). It was noted that the range of 6′-SL concentrations was slightly wider (from 0.25 to 1.08 g/L, average 0.66 g/L) in mothers who delivered preterm (Thurl et al., 2017). Other publications reported maximum concentrations in European human milks up to 1.13 (average 0.10–0.65 g/L; Austin et al., 2019) or 1.31 g/L (average 0.10–0.65 g/L; Samuel et al., 2019). In a recent review (Soyyilmaz et al., 2021), a mean of mean concentrations of 0.40 and 0.71 g/L has been reported for mature and transitional milk, with a maximum mean of 0.74 and 1.30 g/L, respectively.

In consideration of the large and recent data set used in the review by Soyylmaz et al. (2021), the Panel decided to use the values corresponding to the mean of means (0.40 g/L) and the maximum mean (0.74 g/L) as representative of the average natural concentrations found in mature human milk. However, the Panel notes that due to the wide variations of 6′-SL concentrations in human milk (up to 1.08 g/L – Thurl et al., 2017; 1.13 g/L – Austin et al., 2019 and 1.31 g/L Samuel et al., 2019) higher intakes may occur.

Based on the reported mean concentrations of 6′-SL in human milk from Soyylmaz et al. (2021) and considering the average and high daily intakes of human milk (800 and 1,200 mL, respectively) for infants from 0 to 6 months (EFSA NDA Panel, 2013), the daily intake levels of 6′-SL from human milk for a 6.7 kg body weight (bw) infant (EFSA Scientific Committee, 2012) was calculated (Table 4). This default body weight used by the NDA Panel is for infants of 3–6 months of age, who are more likely than younger infants to consume these volumes of human milk.

Table 4: Estimated daily intake levels of 6′-SL from average (800 mL) and high (1,200 mL) human milk intakes for infants of 6.7 kg bw, based on mean and high mean concentrations of 6′-SL of 0.40 and 0.74 g/L, respectively, in mature human milk (Soyyilmaz et al., 2021)

| Daily intake levels (mg/kg bw) from 800 mL of human milk | Daily intake levels (mg/kg bw) from 1,200 mL of human milk |
|----------------------------------------------------------|----------------------------------------------------------|
| Mean concentration | High concentration | Mean concentration | High concentration |
| 6′-SL | 48 | 88 | 72 | 133 |

bw: body weight.

When applying the same approach to the 6′-SL concentrations in human milk reported by Thurl et al. (2017), higher intakes (up to 193 mg/kg bw) are obtained. The concentrations reported by Thurl et al. (2017) were the basis for the Panel’s previous assessment of 6′-SL (EFSA NDA Panel, 2020a).

Furthermore, when considering the 6′-SL concentrations (Soyyilmaz et al., 2021) found in transitional milk (1–2 weeks after delivery; mean and high concentrations of 0.71 and 1.30 g/L, respectively) in an infant weighing 4.8 kg (EFSA Scientific Committee, 2012, default value for 0–3 months), assuming a daily milk intake of 700 mL (EFSA NDA Panel, 2013), the estimated mean and high daily intakes of 6′-SL are 104 and 190 mg/kg bw, respectively.
The Panel noted that although the main component of the NF is 6'-SL sodium salt, other fractions that are also present in human milk, such as α-lactose, sialic acid and N-acetyl-α-glucosamine, are present in the NF in different amounts (see Section 3.4).

3.7. Proposed uses and use levels and anticipated intake

3.7.1. Target population

The target population proposed by the applicant is the general population.

3.7.2. Proposed uses and use levels

The NF is proposed to be used as an ingredient in IF and FOF, processed cereal-based food, milk-based drinks and similar products intended for young children. These food products, defined using the FoodEx2 hierarchy, and the maximum use levels, are reported in Table 5.

The applicant also intends to market the NF in FS, at the maximum daily intake of 1.8 g 6'-SL sodium salt for individuals above 3 years of age or at a maximum daily intake of 0.7 g 6'-SL sodium salt when intended for infants (up to 11 months) or young children (12–35 months).

For the category FSMP, the applicant proposed the use in accordance with the particular nutritional requirements of the persons for whom the products are intended according to Regulation (EU) No 609/2013.

According to the applicant, FS are not intended to be used if other foods with added NF or human milk (for infants and young children) are consumed on the same day.

Table 5: Food categories according to FoodEx2 hierarchy and maximum use levels of the NF intended by the applicant

| FoodEx2code | FoodEx2 level | Food category                                                                 | Max use level (mg NF/100 g) |
|-------------|---------------|-------------------------------------------------------------------------------|-----------------------------|
| A03PZ       | 4             | Infant formulae, powder                                                       | 560(a)                      |
| A03QE       | 4             | Infant formulae, liquid                                                       | 70                          |
| A03QK       | 4             | Follow-on formulae, powder                                                   | 560(a)                      |
| A03QQ       | 4             | Follow-on formulae, liquid                                                    | 70                          |
| A03QZ       | 3             | Cereals with an added high protein food which have to be reconstituted with    | 280(a)                      |
|             |               | water or other protein-free liquid                                            |                             |
| A03QY       | 3             | Simple cereals which have to be reconstituted with milk or other              | 490(a)                      |
|             |               | appropriate nutritious liquids                                                |                             |
| A0BZF       | 3             | Cereals with an added high protein food reconstituted                         | 70                          |
| A0BZE       | 3             | Simple cereals for infants and children, reconstituted                        | 70                          |
| A03RA       | 3             | Biscuits, rusks and cookies for children                                      | 70                          |
| A03RB       | 3             | Pasta for children (dry, to be cooked)                                       | 70                          |
| A03RH       | 3             | Ready-to-eat dairy-based meal for children                                   | 70                          |
| A03RP       | 3             | Special food for children’s growth                                           | 70                          |

(a): Relevant dilution factors (EFSA, 2018) have been used to calculate intake estimates applying the FoodEx2 food classification and description system.

3.7.3. Anticipated intake of the NF

Anticipated intake of 6'-SL sodium salt from the consumption of IF in infants up to 16 weeks of age

IF is expected to be the only food consumed by infants aged 0–16 weeks who are not breastfed. A high consumption of IF has been estimated to be 260 mL/kg bw per day for infants aged 0–16 weeks (EFSA Scientific Committee, 2017). Based on the maximum proposed use level of the NF (0.7 g/L in IF), the high intake of the NF from IF alone is estimated to be 182 mg/kg bw per day.

12 FoodEx2 is an EFSA standardised food classification and description system https://www.efsa.europa.eu/en/data/datastandardisation.
The Panel notes that the anticipated daily intake of the NF from the consumption of IF (only) is higher than the estimated daily intake of 6'-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6'-SL (Table 4).

**Anticipated intake of 6'-SL sodium salt from the proposed uses and use levels of the NF**

EFSA performed an intake assessment of the anticipated daily intake of the NF based on the applicant’s proposed uses and maximum proposed use levels (Table 5) using the EFSA Dietary Exposure (DietEx) Tool, which is based on individual data from the EFSA Comprehensive European Food Consumption Database (EFSA, 2011). The lowest and highest mean and 95th percentile anticipated daily intakes of the NF (on a mg/kg bw basis), among the EU dietary surveys, are presented in Table 6.

The estimated daily intake of the NF for each population group from each EU dietary survey is available in the excel file annexed to this scientific opinion (under supporting information).

**Table 6:** Intake estimate resulting from the use of 6'-SL sodium salt as an ingredient in the intended food categories at the maximum proposed use levels

| Population group | Age (years) | Mean intake (mg/kg bw per day) | P95th intake (mg/kg bw per day) |
|------------------|-------------|--------------------------------|--------------------------------|
|                  |             | Lowest(a)                      | Highest(a)                     |
| Infants          | < 1         | 16                             | 70                             |
| Young children   | 1 to < 3    | 1.0                            | 7.0                            |
| Other children   | 3 to < 10   | 0.0                            | 0.0                            |
| Adolescents      | 10 to < 18  | 0.0                            | 0.0                            |
| Adults           | ≥ 18        | 0.0                            | 0.0                            |

(a): Intakes were assessed for all EU dietary surveys available in the food comprehensive database on 14 September 2022. The lowest and the highest averages observed among all EU surveys are reported in these columns.

(b): Intakes were assessed for all EU dietary surveys available in the food comprehensive database on 14 September 2022. The lowest and the highest P95th observed among all EU surveys are reported in these columns (P95th based on less than 60 individuals are not considered).

(c): Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011).

(d): Includes elderly, very elderly, pregnant and lactating women.

The Panel notes the conservative assumptions underlying the intake assessment, since the content of 6'-SL sodium salt in the NF accounts for only about 95% and therefore, the figures that are calculated considering a 100% purity slightly overestimate the actual intake. Furthermore, the weight contributed by sodium has not been subtracted, which also contributes to overestimation of the 6'-SL intake.

In addition, it is assumed that all foods of the proposed food categories consumed by infants contain the NF at the maximum proposed use levels. With these assumptions the anticipated daily intake of 6'-SL sodium salt from the proposed uses and use levels in infants is higher than the estimated daily intake of 6'-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6'-SL (Table 4).

**3.7.4. Anticipated intake of the NF from food supplements**

The applicant has proposed a maximum daily intake of 1.8 g of the NF as FS for individuals above 3 years of age or at a maximum level of 0.7 g/day when intended for infants (up to 11 months) or young children (12–35 months; Table 7).

**Table 7:** Use of the NF in FS and resulting intake expressed as mg/kg bw per day

| Population group | Age (years) | Body weight(a) (kg) | Use level (mg/day) | Intake (mg/kg bw per day)(b) |
|------------------|-------------|---------------------|--------------------|------------------------------|
| Infants          | < 1         | 5.0                 | 700                | 140                          |
| Young children   | 1 to < 3    | 12.0                | 700                | 58                           |

13 [https://www.efsa.europa.eu/it/science/tools-and-resources/dietex](https://www.efsa.europa.eu/it/science/tools-and-resources/dietex)
The Panel notes that the maximum daily intake of 6'-SL from the use of the NF in FS (i.e. from 700 mg to 1.8 g/day) for any population category is below or is similar (i.e. infants) to the estimated daily intake of 6'-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6'-SL (Table 4).

According to the applicant, FS containing the NF are not intended to be used if other foods with added 6'-SL or human milk (for infants and young children) are also consumed on the same day.

3.7.5. Combined intake from the NF and other sources

The Panel notes that 6'-SL sodium salt is already authorised for use in food categories other than those proposed for the NF under assessment (e.g. use in beverages, flavoured and unflavoured fermented milk-based products, cereal bars – Appendix A)\(^2\). Therefore, the combined intake of 6'-SL sodium salt from the already authorised uses and the currently proposed uses (highest P95th intake of 206 mg/kg bw in infants, Table 8) is higher than the estimated intake based on only the currently proposed uses and use levels (highest P95th intake of 155 mg/kg bw in infants, Table 6). The combined daily intake of 6'-SL sodium salt from the authorised and proposed uses, for each population group from each EU dietary survey, is available in the Excel file annexed to this scientific opinion (under supporting information).

The Panel notes that the maximum daily intake of 6'-SL from the use of the NF in FS (i.e. from 700 mg to 1.8 g/day) for any population category is below or is similar (i.e. infants) to the estimated daily intake of 6'-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6'-SL (Table 4).

According to the applicant, FS containing the NF are not intended to be used if other foods with added 6'-SL or human milk (for infants and young children) are also consumed on the same day.

| Population group | Age (years) | Body weight\(^{(a)}\) (kg) | Use level (mg/day) | Intake \(\text{mg/kg bw per day}^{(b)}\) |
|------------------|-------------|--------------------------|-------------------|-----------------------------------|
| Other children   | 3 to < 10   | 23.1                     | 1,800             | 78                                |
| Young adolescents| 10 to < 14  | 43.4                     | 1,800             | 41                                |
| Old adolescents  | 14 to < 18  | 61.3                     | 1,800             | 29                                |
| Adults           | ≥ 18        | 70.0                     | 1,800             | 26                                |

\(^{(a)}\): Default and average body weights for each population group are available in EFSA Scientific Committee, 2012.

\(^{(b)}\): Intake in “mg/kg bw per day” are calculated by considering the use levels in “mg/day” and default body weights defined in EFSA Scientific Committee (2012).

\(^{(c)}\): Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011).

The Panel notes that the maximum daily intake of 6'-SL from the use of the NF in FS (i.e. from 700 mg to 1.8 g/day) for any population category is below or is similar (i.e. infants) to the estimated daily intake of 6'-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6'-SL (Table 4).

According to the applicant, FS containing the NF are not intended to be used if other foods with added 6'-SL or human milk (for infants and young children) are also consumed on the same day.

Table 8: Intake estimate resulting from the combined uses of 6'-SL sodium salt from both authorised and proposed food categories at the maximum use levels

| Population group | Age (years) | Mean intake \(\text{mg/kg bw per day}\) | P95th intake \(\text{mg/kg bw per day}\) |
|------------------|-------------|----------------------------------------|----------------------------------------|
|                  |             | Lowest\(^{(a)}\) | Highest\(^{(a)}\) | Lowest\(^{(b)}\) | Highest\(^{(b)}\) |
| Infants          | < 1         | 23          | 95          | 66          | 206          |
| Young children\(^{(c)}\) | 1 to < 3   | 11          | 47          | 29          | 159          |
| Other children   | 3 to < 10   | 4.1          | 15          | 9.5          | 26           |
| Adolescents      | 10 to < 18  | 0.7          | 5.8         | 3.0          | 13           |
| Adults\(^{(d)}\)  | ≥ 18        | 2.3          | 3.0         | 5.2          | 7.5           |

\(^{(a)}\): Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 14 September 2022. The lowest and the highest averages observed among all EU surveys are reported in these columns.

\(^{(b)}\): Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 14 September 2022. The lowest and the highest P95th observed among all EU surveys are reported in these columns (P95th based on less than 60 individuals are not considered).

\(^{(c)}\): Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011).

\(^{(d)}\): Includes elderly, very elderly, pregnant and lactating women.

The Panel notes that the highest estimated 95th percentile daily intake in infants and young children from the combined exposure (i.e. 206 and 159 mg/kg bw, respectively; Table 8) from the maximum authorised and proposed uses, is slightly higher than the estimated daily intake from the authorised uses alone (i.e. 192 and 147 mg/kg bw, respectively; EFSA NDA Panel, 2020b), and higher than the estimated daily intake of 6'-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6'-SL (Table 4).

Additional sources for the oligosaccharides contained in the NF will be human milk, cow milk, fermented milk-based products and selected cheeses retaining milk sugar (e.g. curd cheese). However, in comparison to the natural intake of 6'-SL from human milk (Table 4) and the intake from the
suggested uses and use levels of the NF, the contribution from consumption of cow milk and milk-derived products is small.

### 3.8. Absorption, distribution, metabolism and excretion (ADME)

No ADME data have been provided for the NF.

As reported in previous EFSA opinions (EFSA NDA Panel, 2019a,b,c, 2020a,b, 2021, 2022a,c,e), HMOs, including 6′-SL, are considered ‘non-digestible oligosaccharides’ (EFSA NDA Panel, 2014) since they do not undergo any significant digestion in the upper gastrointestinal tract (Brand-Miller et al., 1995, 1998; Engfer et al., 2000; Gnoth et al., 2000; Chaturvedi et al., 2001; Rudloff and Kunz, 2012).

Brand-Miller et al. (1995, 1998) reported that HMOs, consumed as a load (a purified oligosaccharide fraction from human milk), are fermented in the colon by the intestinal microbiota. Chaturvedi et al. (2001) and Coppa et al. (2001) reported that 97% and 40%–50%, respectively, of the ingested HMOs are excreted unchanged in faeces of breastfed infants. Furthermore, approximately 1–2% of the ingested amounts of HMOs is excreted unchanged in the infants’ urine (Rudloff et al., 1996, 2006; Goehring et al., 2014; Kunz et al., 2017; EFSA NDA Panel, 2019a,b).

Based on information available on HMOs, the Panel considers that the NF does not undergo any significant digestion in the gastrointestinal tract and that only small amounts are expected to be absorbed. Moreover, there are no indications that the absorption of 6′-SL, which is the main constituent of the NF, or other structurally related mono- and oligosaccharides (e.g. D-lactose), differs from that of similar components in human milk (EFSA NDA Panel, 2020a).

### 3.9. Nutritional information

The NF is mainly composed by the non-digestible oligosaccharide 6′-SL.

The NF contains other carbohydrates, individually present at low concentrations. D-Lactose is the most abundant component of human milk (~7%) and its monomers, D-glucose and D-galactose, are normal constituents of human milk. Sialic acid is an endogenous human and ubiquitous monosaccharide (EFSA NDA Panel, 2017; Röhrig et al., 2017), while 6′-sialyllactulose is derived from 6′-SL by isomerisation of the terminal D-glucose moiety into D-fructose mainly under alkaline conditions during the production process (Zeng et al., 2018). N-acetyl-D-glucosamine is also present in human milk as a building block for oligosaccharides (Garrido et al., 2012).

The Panel notes that the NF, being a sodium salt, may contribute to the daily sodium intake. In its opinion on DRVs for sodium, the NDA Panel has provided advice on the levels of sodium intake that are considered safe and adequate14,15 for population groups aged 1 year and older (EFSA NDA Panel, 2019c). Considering the maximum sodium content in the NF of 4.2%, the intake of sodium from the NF is expected to represent about 7% (up to 80 mg sodium/day) of the sodium intake of 1.1 g/day considered as safe and adequate for young children (1–3 years). For other children and adults, the intake of sodium from the NF is lower than 1% of the sodium intake level that is considered safe and adequate for these age groups.

As for infants up to the age of 6 months consuming IF, the maximum sodium intake from the NF would be approximately 50 mg/day considering a daily intake of IF of 260 mL/kg bw and a body weight of 6.7 kg. This corresponds to about 40% of the daily sodium intake of exclusively breastfed infants (120 mg sodium/day during the first 6 months; EFSA NDA Panel, 2019c).

For older infants aged 7–11 months, the Panel established an adequate intake (AI)14 of 200 mg sodium/day (EFSA NDA Panel, 2019c). In this age group, the maximum sodium intake from the NF is estimated to be approximately 58 mg sodium/day, which corresponds to about 30% of the AI.

The Panel considers that, taking into account the composition of the NF and the proposed conditions of use, consumption of the NF is not nutritionally disadvantageous.

### 3.10. Toxicological information

The applicant provided three toxicological studies on a mixture of HiMOs containing the NF, which were conducted in compliance with OECD (Organisation for Economic Co-operation and Development)
principles of Good Laboratory Practices (GLP) (OECD, 1998) and in accordance with the OECD test guidelines (TG) 471 (OECD, 1997), 487 (OECD, 2016) and 408 (OECD, 2018). An additional preliminary in vivo repeated dose study was also carried out. These studies were conducted with a mixture of HiMOs composed by 2’-FL (47.1%), 3’-FL (16.0%), LNT (23.7%), 3’-SL sodium salt (4.1%), 6’-SL sodium salt (4.0%) and other carbohydrates (5.1%). Another GLP-compliant 90-day study was also conducted with the NF alone. These studies, which were claimed proprietary by the applicant, are listed in Table 9.

An article on the assessment of the NF in the above-mentioned mixture of HiMOs, which describes the studies listed in Table 9, was provided (Parschat et al., 2020). The applicant also provided a publication where a toxicological evaluation of 6’-SL sodium salt produced by different enzymatic synthesis (Gurung et al., 2018) is reported.

An article on the assessment of the NF in the above-mentioned mixture of HiMOs, which describes the studies listed in Table 9, was provided (Parschat et al., 2020). The applicant also provided a publication where a toxicological evaluation of 6’-SL sodium salt produced by different enzymatic synthesis (Gurung et al., 2018) is reported.

3.10.1. Genotoxicity

The in vitro assessment of the mutagenic potential of the mixture of HiMOs containing the NF was performed with S. Typhimurium strains TA98, TA100, TA102, TA1535 and TA1537, which were exposed to the mixture diluted in water at six different concentrations up to 600 mg mixture/plate, either in the presence or absence of liver microsomal fractions (S9). No reproducible or dose-related increases in revertant colony numbers over control counts were observed with any of the strains following exposure to the mixture of HiMOs at any concentration (irrespective of the presence or absence of S9). No evidence of toxicity was obtained following exposure to the mixture of HiMOs. Therefore, the

| Reference | Type of study | Test system | Dose |
|-----------|---------------|-------------|------|
| Unpublished study, LPT No. 35908 (Parschat et al., 2020) | Bacterial reverse mutation test (GLP, OECD TG 471) mixture of HiMOs | Salmonella Typhimurium TA98, TA100, TA102, TA1535 and TA1537 | 0.8–24 mg 6’-SL/plate (absence and presence of S9 mix) |
| Unpublished study, LPT No. 35909 (Parschat et al., 2020) | In vitro mammalian cell micronucleus test in human peripheral blood lymphocytes (GLP, OECD TG 487) mixture of HiMOs | Human peripheral blood lymphocytes | 0.3–2.4 mg 6’-SL/mL for 4 or 24 h (absence and presence of S9 mix) |
| Unpublished study, LPT No. 35504 (Parschat et al., 2020) | 7-day repeated dose oral toxicity study (pilot study) mixture of HiMOs | Sprague Dawley rats (females only) | Dietary exposure ranging from 6.7 and 13.7 g/kg bw/day (mean 6’-SL intake: 0.27–0.55 g/kg bw/day) |
| Unpublished study, LPT No. 35907 (Parschat et al., 2020) | 90-day repeated dose oral toxicity study (GLP, OECD TG 408, limit test) mixture of HiMOs | Sprague Dawley rats | Overall dietary exposure of 6.3 g/kg bw of HiMO mixture (mean 6’-SL intake: 0.20–0.28 g/kg bw/day in males and 0.25–0.32 g/kg bw/day in females) |
| Unpublished study, LPT No. 36546 | 90-day repeated dose oral toxicity study (GLP, OECD TG 408, limit test) 6’-SL alone | Sprague Dawley rats | Overall dietary exposure of 6.87 g 6’-SL/kg bw (mean 6’-SL intake: 5.0–7.4 g/kg bw/day in males and 6.3–9.3 g/kg bw/day in females) |

The Panel also noted that in solution under acidic conditions, the NF will be hydrolysed to α-lactose and sialic acid (EFSA NDA Panel, 2020a). The amount of sialic acid potentially formed at the maximum concentration and intake (i.e. infants at 95th percentile, Table 4) would be about 3 mg/kg bw, which is lower than the intake based on natural levels in human milk (i.e. 11 mg/kg bw, EFSA NDA Panel, 2017). Another monosaccharide, N-acetyl-α-glucosamine, can be found in the NF at concentrations up to 1.5 g/L (Chen et al., 2010).

Under alkaline conditions, 6’-sialyllactulose would also be formed although the content would remain very low (up to 4.6 mg/kg bw) and is considered not of concern (suggested use in infants to treat constipation is 2.5 mL syrup/day corresponding to approximately 1.65 g lactulose/day (250 mg/kg bw for an infant weighing 6.7 kg)).

3.10.2. Safety of 6’-sialyllactose sodium salt
mixture of HiMOs was shown to be non-mutagenic at concentrations up to 600 mg/plate (corresponding to 24 mg/plate of 6'-SL), in the absence or presence of metabolic activation.

In the in vitro mammalian cell micronucleus test, five concentrations of the mixture of HiMOs up to 60 mg/mL were tested in cultured human peripheral blood lymphocytes in the presence or absence of metabolic activation (S9 fraction). No statistically significant increases in the number of binucleate cells containing micronuclei both after 4-h treatment in the presence of S9 mix or following 24-h treatment in the absence of S9 were recorded. The mixture of HiMOs did not show any evidence of clastogenicity or aneugenicity in the absence and presence of metabolic activation up to the highest concentration of 60 mg/mL (corresponding to 2.4 mg 6'-SL/mL).

Taking into account the results provided and considering the nature, source and production process of the NF, the Panel considers that there are no concerns regarding genotoxicity.

3.10.2. Subchronic toxicity

The applicant provided a 7-day repeated dose pilot toxicity study, where two groups of five Crl:CD (Sprague Dawley (SD)) female rats were given ad libitum a standard diet with and without 10% (w/w) of the mixture of HiMOs, containing 4% of 6'-SL. The calculated intake of the mixture ranged from 6.7 to 13.7 g/kg bw per day, corresponding to a 6'-SL intake of 0.27–0.55 g/kg bw per day. There were no deaths or any relevant variations in clinical signs, food consumption or body weight. Clinical pathology investigations and post-mortem observations were not performed.

In the 90-day study (limit test) groups of 10 Crl:CD(SD) rats/sex were given ad libitum a standard diet with or without 10% (w/w) of the mixture of HiMOs (same composition as in the pilot study). The mean intake of the test item ranged from 5.01 to 6.88 g/kg bw per day (mean of 5.67) for the male animals and from 6.26 to 7.91 g/kg bw per day (mean of 6.97) for the female animals. The corresponding mean daily intake of 6'-SL has been calculated as 0.227 and 0.279 g/kg bw for male and female rats, respectively.

There were no deaths in the course of the study and no treatment-related clinical signs were observed in any rats. Episodes of increased or decreased food consumption were recorded in treated males in comparison to the control group. Body weight and body weight gain were not affected by the treatment. Some statistically significant changes were noted: reduced spontaneous motility was observed in treated male rats in the absence of any other change in functional observation tests and a slight increase in body temperature was noted in female rats.

Statistically significant variations in haematological (decrease of neutrophils (11%) in females) and clinical chemistry parameters (decrease in proteins (9%, both albumin and globulin and increase in albumin/globulin ratio) and alanine aminotransferase (24%), increase in urea (16%) in females) and urinalysis (decrease in specific gravity (1%) in females) were recorded. Furthermore, a decrease in absolute brain weight (2.9%) in treated males and relative kidney weight (about 10%) in female rats was also noted. In male animals at histological examination, a small increase in the incidence and magnitude of hepatocellular lipid content in periportal areas was recorded. No other gross or histopathologic findings in treated rats were noted.

The changes observed were of low magnitude and limited to only one sex and, overall, they are considered by the Panel as not biologically relevant. The Panel considers that no adverse effects were observed in this study at the tested dose corresponding to 0.23 g 6'-SL/kg bw per day.

For the 90-day study performed with 6'-SL sodium salt alone, groups of 10 SD rats/sex were given ad libitum a standard diet with or without 10% (w/w) of the NF (91% of 6'-SL). The concentration remained constant throughout the study while the control animals received standard diet only. The mean test item intake per week ranged from 5.04 to 7.41 g/kg bw/day for the male animals (mean of 6.04 g/kg bw/day) and from 6.29 to 9.32 g/kg bw/day for the female animals (mean of 7.69 g/kg bw/day).

There were no deaths in the course of the study and no treatment-related clinical signs were observed. A decrease in body weight gain was noted in treated males from study day 36 up to the end of the study with a statistically significant decrease in body weight vs control rats from day 36 and with a maximum decrease of 7% on day 90. In the same rats an increase in food consumption was noted mainly throughout the second half of the treatment period. Episodes of increased food consumption were noted in female rats, too. Other statistically significant changes were found in the functional tests, with increased grip strength for both forelimbs and hindlimbs in females at the end of the treatment period. In addition, statistically significant changes in haematological parameters (decrease of erythrocytes (3% and 6.5%) in females and males, respectively; increase in reticulocytes
53% and mean corpuscular volume and mean corpuscular haemoglobin 2.6% in males) and clinical chemistry parameters (decrease in triglycerides (27%) in males, chloride (1.8%) and sodium (1.2%) in females; increase in albumin/globulin ratio (6.3%) and urea (30%) in males) at the end of the treatment period were recorded.

Finally, other statistically significant changes in organ weights at post-mortem examination were noted, specifically increases in absolute (10%–12%) and relative (19%–21%) kidney weight, a decrease in thymus weight (16% relative, 24% absolute) and relative testis weight (15%–16%) in male rats. In female rats, a decrease in absolute (11%) and relative (16%) left adrenal weights and an increase (13%) in the absolute right kidney weight were recorded. Whilst the decrease in thymus weight was not accompanied by relevant histopathologic changes, the increased kidney weights correlated with the histopathological findings in the kidneys: deposits underneath the urothelial lining or within the renal pelvis in 5 out of 10 males and 2 out of 10 females exposed to 6'-SL were noted. Urothelial hyperplasia was observed and considered related to the mineral deposits in 4 out of 10 males and 1 out of 10 females. Minimal to slight papillary necrosis was observed in 3 out of 10 males and 1 out of 10 females exposed to 6'-SL in the diet. Since the (tip of the) papilla was not present in the sections of at least one of both kidneys in 2 out of 10 control males and females and in 6 out of 10 males and 5 out of 10 females of the group receiving the diet with 6'-SL, the actual incidence could well be higher. In the urinary bladder, deposits were present in 2 out of 10 males exposed to 6'-SL. The deposits were found intra- and sub-urothelial. Urothelial hyperplasia in 7 out of 10 males and 4 out of 10 females exposed to 6'-SL was recorded. Minimal, focal erosion was also noted in 1 male rat of the group that received 6'-SL.

Following a request from EFSA, investigations were performed by the applicant to identify the nature of the microscopic kidney deposits. Using von Kossa staining and polarised light to analyse the kidney tissues, it was shown that the precipitates were composed of calcium phosphate. It is known that dietary administration of sodium salts (e.g. sodium saccharin, from 5% in the diet) can alter urinary composition and increase in the rat the incidence of renal papillary necrosis or vascular changes of the renal papilla through formation of calcium phosphate-containing precipitates in the kidney and urinary bladder (Cohen, 1999; Cohen et al., 2000). In this respect, the combination of some critical factors (e.g. urinary pH and proteins, levels of calcium and phosphate) plays a role mainly in the male rats, that are the most susceptible species and sex. Urothelial hyperplasia represents a reactive response to the precipitate that exerts a cytotoxic effect and it is followed by regenerative responses (IARC, 1999).

The Panel considers that, in agreement with previous assessments (NTP, 1997, 1999; IARC, 1999), the precipitates formation and resulting reactions are a species-specific high dose effect observed in the rat (with the male sex being more sensitive) and in consideration of the interspecies differences these findings are judged as not relevant to humans.

### 3.10.3. Human data

No human intervention studies conducted with 6'-SL sodium salt alone have been provided by the applicant.

The Panel noted that a double-blind, controlled, randomised interventional study was conducted in infants with the IF containing the mixture of HiMOS (Parschat et al., 2021; EFSA NDA Panel, 2022a). The safety and tolerability profile of the HiMO mixture – IF appeared similar to the commercialised IF alone used as a comparator. The Panel considers this information as supportive for the assessment of 6'-SL.

The applicant provided references to clinical studies (Meli et al., 2014; Simeoni et al., 2016; Cooper et al., 2017; Radke et al., 2017) conducted in infants where tolerability of IF supplemented with bovine milk-derived oligosaccharides up to 10 g/L formula (including unspecified amount of 6'-SL) was assessed. As for 3'-SL sodium salt (EFSA NDA Panel, 2022a) the Panel considers that the test materials used in these studies are not representative of the NF and that therefore the results are of limited value for the safety assessment of the NF.

### 3.11. Allergenicity

The applicant did not identify any allergenic potential of introduced proteins as a result of the genetic modification of the *E. coli* BL21 (DE3) host strain, according to the Scientific opinion on the
assessment of allergenicity of GM plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms’ (EFSA GMO Panel, 2010). The criterion used for identifying allergenic proteins was that of considering “higher than 35% identity in a sliding window of 80 amino acids”.

The protein content in the NF is low (≤ 0.01%) as indicated in the specifications (Table 3).

The Panel considers that, for these reasons, the likelihood of allergenic reactions to the NF is low.

4. Discussion

The NF is a powdered mixture mainly composed of the sodium salt of the HiMO 6′-SL, but it also contains α-lactose, sialic acid, N-acetyl-D-glucosamine and 6′-sialyllactulose, and a small fraction of other related saccharides. The NF is obtained by fermentation with two genetically modified strains of E. coli BL21 (DE3), the production strain and the optional degradation strain.

The applicant intends to add the NF to a variety of foods, including IF and FOF, FSMP and FS. The target population proposed by the applicant is the general population.

Considering that 6′-SL is a naturally occurring oligosaccharide present in human milk, the history of human exposure to 6′-SL concerns breastfed infants. The intake of 6′-SL in breastfed infants on a body weight basis is expected to be safe also for other population groups.

In the 90-day study performed with 6′-SL sodium salt alone (mean intake of 6.04 to 7.69 g/kg bw/day for males and females, respectively) adverse effects in the kidney and urinary bladder were noted including presence of intra- and sub-urothelial deposits, urothelial hyperplasia and papillary necrosis. It is considered that high doses of the sodium salt given with the NF can cause altered urinary composition and formation of calcium phosphate-containing precipitate (Cohen, 1999, 2018), which could lead to papillary necrosis. As also previously reported (NTP, 1997, 1999; IARC, 1999; Cohen, 2018), the rat (especially males) is sensitive to these effects and given the interspecies differences, the findings are judged as not relevant to humans. The Panel notes that in other toxicity studies conducted with an identical 6′-SL (administered by gavage) no similar findings were reported. In those studies the amount of administered 6′-SL sodium salt was lower (5 g/kg bw/day) while the amount of sodium in the batch(es) used was approximately halved (EFSA NDA Panel, 2020b) or not reported (Gurung et al., 2018). The Panel also notes that the highest amount of sodium intake in infants further to the use of the NF (i.e. 8.7 mg sodium/kg bw from the combined intake in infants) corresponds to about 58 mg sodium/day. The Panel notes that the adequate intake (AI) is of 200 mg sodium/day (EFSA NDA Panel, 2019c).

The Panel notes that the anticipated daily intake of 6′-SL from the consumption of IF (only), in infants up to 16 weeks of age, is higher than the estimated daily intake of 6′-SL of 133 mg/kg bw in high consuming breast-fed infants of women with high mean concentration of 6′-SL. The anticipated daily intake of 6′-SL from both proposed and combined (authorised and proposed) uses at their respective maximum use levels in infants and young children is also above the current estimated high mean intake of 6′-SL from human milk in infants on a body weight basis. The Panel also notes that the highest estimated daily intake from the combined exposure (from the maximum authorised and proposed uses – Table 8), is similar to the estimated daily intake from the authorised uses alone (EFSA NDA Panel, 2020a). Furthermore, the Panel noted that, in the light of the updated and expanded database modifying the concentrations of 6′-SL in human milk (Soyyilmaz et al., 2021), the estimated average natural intake was lowered from 193 mg/kg bw (EFSA NDA Panel, 2020b) to 133 mg/kg bw. Finally, it is also noted (Section 3.6.2) that even concentrations of 6′-SL higher than those reported by Thurl et al. (2017) have been identified (Austin et al., 2019; Samuel et al., 2019).

Given the wide range of intakes from breast milk, the conservative assumptions underlying the intake assessment, the intrinsic nature of HMOs with their limited absorption, and the absence of toxicologically relevant effects related to 6′-SL in the subchronic studies, the Panel does not have safety concerns related to the estimated intakes of the NF.

The applicant stated that FS containing the NF are not intended to be used if other foods or human milk (for infants and young children) with added NF are consumed on the same day. Additional sources for the oligosaccharides contained in the NF are cow milk and milk-derived products. However, the contribution from consumption of cow milk and milk-derived products is small.

Finally, it is noted that, in line with other milk oligosaccharides that are natural components of human milk, the safety assessment of this NF is mainly based on the comparison between the intake of breastfed infants and the estimated intake as NF.
5. Conclusions

The Panel concludes that the NF, which is composed of 6’S-L and other structurally related mono- and oligosaccharides, is safe under the proposed conditions of use.

5.1. Protection of proprietary data in accordance with article 26 of Regulation (EU) 2015/2283

The Panel could not have reached the conclusion on the safety of the NF under the proposed conditions of use without the data claimed as proprietary by the applicant: (i) identity of the NF as confirmed by MS, NMR spectroscopy and HPAEC-PAD; (ii) toxicological information, including in vitro genotoxicity studies, subacute and subchronic toxicity studies (Table 9); (iii) description and certificates of deposition of the genetically modified production and optional degradation strains, and qPCR detection system and method validation reports for the production and optional degradation strains; (iv) method validation reports for the determination of 6’S-L and carbohydrate by-products in the NF using HPAEC-PAD.

6. Steps taken by EFSA

1) On 11 December 2020 EFSA received a letter from the European Commission with the request for a scientific opinion on the safety of 6’S-sialyllactose (6’S-L) sodium salt. Ref. Ares (2020)7530911.

2) On 11 December 2020, a valid application on 6’S-L sodium salt, which was submitted by Chr. Hansen A/S, was made available to EFSA by the European Commission through the Commission e-submission portal (NF 2020/1801) and the scientific evaluation procedure was initiated.

3) On 14 April 2021, EFSA received a letter from the European Commission with the updated request for a scientific opinion on the safety of (6’S-L) sodium salt. Ref. Ares(2021)2527692.

4) On 14 April 2021, a valid application on 6’S-L sodium salt was made available to EFSA by the European Commission through the Commission e-submission portal and the scientific evaluation procedure was restarted.

5) On 22 April 2021, EFSA requested the applicant to provide additional information to accompany the application and the scientific evaluation was suspended.

6) On 01 July 2022, additional information was provided by the applicant through the Commission e-submission portal and the scientific evaluation was restarted.

7) During its meeting on 26 October 2022, the NDA Panel, having evaluated the data, adopted a scientific opinion on the safety of 6’S-L sodium salt as a NF pursuant to Regulation (EU) 2015/2283.

References

Albrecht S, Lane JA, Marino K, Al Busadah KA, Carrington SD, Hickey RM and Rudd PM, 2014. A comparative study of free oligosaccharides in the milk of domestic animals. British Journal of Nutrition, 111, 1313–1328.

Aldredge DL, Geronimo MR, Hua S, Nwosu CC, Lebrilla CB and Barile D, 2013. Annotation and structural elucidation of bovine milk oligosaccharides and determination of novel fucosylated structures. Glycobiology, 23, 664–676.

Asakuma S, Akahori M, Kimura K, Watanabe Y, Nakamura T, Tsunemi M, Arai I, Sanai Y and Urashima T, 2007. Sialyl oligosaccharides of human colostrum: changes in concentration during the first three days of lactation. Bioscience, Biotechnology and Biochemistry, 71, 1447–1451.

Austin S, De Castro CA, Benet T, Hou Y, Sun H, Thakkar SK, Vinyes-Pares G, Zhang Y and Wang P, 2016. Temporal change of the content of 10 oligosaccharides in the milk of Chinese urban mothers. Nutrients, 8, 346.

Austin S, De Castro CA, Sprenger N, Binia A, Affolter M, Garcia-Rodenas CL, Beauport L, Tolsa JF and Fischer Fumeaux CJ, 2019. Human milk oligosaccharides in the milk of mothers delivering term versus preterm infants. Nutrients, 11, 1282.

Bode L, 2012. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology, 22, 1147–1162.

Brand-Miller JC, McVeagh P, McNeil Y and Gillard B, 1995. Human milk oligosaccharides are not digested and absorbed in the small intestine of young infants. Proceedings of the Nutrition Society of Australia, 19, 44.

Brand-Miller JC, McVeagh P, McNeil Y and Messer M, 1998. Digestion of human milk oligosaccharides by healthy infants evaluated by the lactulose hydrogen breath test. The Journal of Pediatrics, 133, 95–98.

Chart H, Smith HR, La Ragione RM and Woodward MJ, 2000. An investigation into the pathogenic properties of Escherichia coli strains BLR, BL21, DHSalphea and EQ1. Journal of Applied Microbiology, 89, 1048–1058.
Chaturvedi P, Warren CD, Buescher CR, Pickering LK and Newburg DS, 2001. Survival of human milk oligosaccharides in the intestine of infants. In: DS Newberg (ed). Bioactive Components of Human Milk. Advances in Experimental Medicine and Biology, Vol. 501. Springer Science+Business Media, New York. pp. 315–323.

Chen JK, Shen CR and Liu CL, 2010. N-Acetylgalcosamine: production and applications. Marine Drugs, 8, 2493–2516.

Cohen SM, 1999. Species differences in thyroid, kidney and urinary bladder carcinogenesis. In: J Capen, E Dybing, J Rice and JD Wilbourn (eds). IARC Scientific Publications, 147th Edition, Issue 147. IARC Scientific Publications. pp. 175–189. http://www.ncbi.nlm.nih.gov/pubmed/10627184

Cohen SM, 2018. Screening for human urinary bladder carcinogens: two-year bioassay is unnecessary. Toxicological Research, 2018(7), 565.

Cohen SM, Arnold LL, Cano M, Ito M, Garland EM and Shaw RA, 2000. Calcium phosphate-containing precipitate and the carcinogenicity of sodium salts in rats. Carcinogenesis, 21(4), 783–792. https://doi.org/10.1093/carcin/21.4.783

Cooper P, Bolton KD, Velaphi S, de Groot N, Emady-Azar S, Pecquet S and Steenhout P, 2017. Early benefits of a starter formula enriched in prebiotics and probiotics on the gut microbiota of healthy infants born to hiv+mothers: a randomized double-blind controlled trial. Clinical Medicine Insights: Pediatrics, 10, 119–130.

Coppa GV, Pierani P, Zampini L, Carloni I, Carlucci A and Gabrielli O, 1999. Oligosaccharides in human milk during different phases of lactation. Acta Paediatrica, 430, 89–94.

Coppa GV, Pierani P, Zampini L, Bruni S, Carloni I and Gabrielli O, 2001. Characterization of oligosaccharides in milk and faeces of breast-fed infants by high-performance anion-exchange chromatography. Advances in Experimental Medicine and Biology, 501, 307–314.

Coppa GV, Gabrielli O, Zampini L, Galeazzi T, Ficcadenti A, Padella L, Santoro L, Soldi S, Carlucci A, Bertino E and Morelli L, 2011. Oligosaccharides in 4 different milk groups, bifidobacteria, and Ruminococcus obeum. Journal of Pediatric Gastroenterology and Nutrition, 53, 80–87.

EFSA (European Food Safety Authority), Arcella D, Ioannidou S and Sousa R, 2018. Internal report on the characterisation of microorganisms used as feed additives or as production organisms. EFSA Journal 2018;16(3):5206, 24 pp. https://doi.org/10.2903/j.efsa.2018.5206

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2019a. Scientific opinion on nutrient requirements and dietary intakes of infants and young children in the European Union. EFSA Journal 2013;11(10):3408, 103 pp. https://doi.org/10.2903/j.efsa.2013.3408

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific opinion on the essential composition of infant and follow-on formulae. EFSA Journal 2014;12(7):3760, 106 pp. https://doi.org/10.2903/j.efsa.2014.3760

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015a. Scientific opinion on the safety of 2′-O-fucosyllactose as a novel food ingredient pursuant to Regulation (EC) No 258/97. EFSA Journal 2015;13(7):4184, 32 pp. https://doi.org/10.2903/j.efsa.2015.4184

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015b. Scientific opinion on the safety of lacto-N-neotetraose as a novel food ingredient pursuant to Regulation (EC) No 258/97. EFSA Journal 2015;13(7):4183, 32 pp. https://doi.org/10.2903/j.efsa.2015.4183

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015c. Statement on the safety of lacto-N-neotetraose and 2′-O-fucosyllactose as novel food ingredients in food supplements for children. EFSA Journal 2015;13(11):4299, 11 pp. https://doi.org/10.2903/j.efsa.2015.4299

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. Guidance on the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2017. Scientific opinion on the safety of synthetic N-acetyl-D-neuraminic acid as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal 2017;15(7):4918, 28 pp. https://doi.org/10.2903/j.efsa.2017.4918

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2019a. Scientific opinion on the safety of 2′-fucosyllactose/difucosyllactose mixture as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2019;17(6):5717, 23 pp. https://doi.org/10.2903/j.efsa.2019.5717

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2019b. Scientific opinion on the safety of lacto-N-tetraose (LNT) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2019;17(12):5907, 27 pp. https://doi.org/10.2903/j.efsa.2019.5907
EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2019c. Scientific opinion on the dietary reference values for sodium. EFSA Journal 2019;17(9):5778, 191 pp. https://doi.org/10.2903/j.efsa.2019.5778

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2020a. Scientific opinion on the safety of 6’-sialyllactose (6’-SL) sodium salt as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2020;18(5):6097, 23 pp. https://doi.org/10.2903/j.efsa.2020.6097

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2020b. Scientific opinion on the safety of 3’-sialyllactose (3’-SL) sodium salt as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2020;18(5):6098, 22 pp. https://doi.org/10.2903/j.efsa.2020.6098

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2020c. Scientific opinion on the safety of lacto-N-neotetraose (LNNt) produced by derivative strains of Escherichia coli BL21 as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2020;18(11):6305, 11 pp. https://doi.org/10.2903/j.efsa.2020.6305

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2021. Scientific opinion on the safety of 3-FL (3-Fucosyllactose) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2021;19(6):6662, 25 pp. https://doi.org/10.2903/j.efsa.2021.6662

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2022a. Scientific opinion on the safety of 3’-sialyllactose (3’-SL) sodium salt produced by derivative strains of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2022;20(5):7331, 26 pp. https://doi.org/10.2903/j.efsa.2022.7331

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2022b. Scientific opinion on the safety of the extension of use of 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNNt) as novel foods in food supplements for infants pursuant to Regulation (EU) 2015/2283. EFSA Journal 2022;20(5):7257, 9 pp. https://doi.org/10.2903/j.efsa.2022.7257

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2022c. Scientific opinion on the safety of lacto-N-tetraose (LNT) produced by derivative strains of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2022;20(5):7242, 24 pp. https://doi.org/10.2903/j.efsa.2022.7242

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2022d. Scientific opinion on the safety of the extension of use of 2’-fucosyllactose/difucosyllactose (2’-FL/DFL) mixture and lacto-N-tetraose (LNT) as novel foods in food supplements for infants pursuant to Regulation (EU) 2015/2283. EFSA Journal 2022;20(3):7140, 9 pp. https://doi.org/10.2903/j.efsa.2022.7140

EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2022e. Scientific opinion on the safety of 3-fucosyllactose (3-FL) produced by a derivative strain of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA Journal 2022;20(5):7329, 23 pp. https://doi.org/10.2903/j.efsa.2022.7329

EFSA Scientific Committee, 2012. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579, 32 pp. https://doi.org/10.2903/j.efsa.2012.2579

EFSA Scientific Committee, 2017. Guidance on the risk assessment of substances present in food intended for infants below 16 weeks of age. EFSA Journal 2017;15(5):4849, 58 pp. https://doi.org/10.2903/j.efsa.2017.4849

Engfer MB, Stahl B, Finke B, Sawatzki G and Daniel H, 2000. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. The American Journal of Clinical Nutrition, 71, 1589–1596.

Garrido D, Ruiz-Moyano S and Mills DA, 2012. Release and utilization of N-acetyl-D-glucosamine from human milk oligosaccharides by Bifidobacterium longum subsp. infantis. Anaerobe, 18, 430–435.

Gnoth MJ, Kunz C, Kinne-Saffran E and Rudloff S, 2000. Human milk oligosaccharides are minimally digested in vitro. The Journal of Nutrition, 130, 3014–3020.

Goehring KC, Kennedy AD, Prieto PA and Buck RH, 2014. Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. PLoS One, 9, e101692.

Gurung RB, Kima DH, Kima L, Leeb AW, Wangc Z and Gaoc Y, 2018. Toxicological evaluation of 6’-sialyllactose (6’-SL) sodium salt. Regulatory Toxicology and Pharmacology, 95, 182–189.

IARC, 1999. IARC monographs programme on the evaluation of carcinogenic risks to humans. In: IARC monographs on the evaluation of carcinogenic risks to humans – Saccharin and its salts (Vol. 73).

Jeong H, Barbe V, Lee CH, Vallenet D, Yu DS, Choi SH, Couloux A, Lee SW, Yoon SH, Cattolico L, Hur CG, Park HS, Ségurens B, Kim SC, Oh TK, Lenski RE, Studier FW, Daegelen P and Kim JF, 2009. Genome sequences of Escherichia coli B strains REL606 and BL21(DE3). Journal of Molecular Biology, 394, 644–652.

Kunz C, Meyer C, Collado MC, Geiger L, Garcia-Mantrana I, Bertua-Rios B, Martinez-Costa C, Borsch C and Rudloff S, 2017. Influence of gestational age, sex, and Lewis blood group status on the oligosaccharide content of human milk. Journal of Pediatric Gastroenterology and Nutrition, 64, 789–798.

McGuire MK, Meehan CL, McGuire MA, Williams JE, Foster J, Sellin DW, Kamau-Mbuthia EW, Kamundia EW, Mbugua S, Moore SE, Prentice AM, Kvist LJ, Otoo GE, Brooker SL, Price WJ, Shafi B, Placec C, Lackey KA, Robertson B, Manzano S, Ruiz L, Rodriguez JM, Pareja RG and Bode L, 2017. What’s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. The American Journal of Clinical Nutrition, 105, 1086–1100.
Meli F, Puccio G, Cajazzo C, Ricottone GL, Pecquet S, Sprenger N and Steenhout P, 2014. Growth and safety evaluation of infant formulae containing oligosaccharides derived from bovine milk: a randomized, doubleblind, noninferiority trial. BioMedCentral Pediatrics, 14, 306.

NTP (National Toxicology Program), 1997. NTP report on carcinogens – background document on saccharin. Prepared for the meeting of the report on Carcinogens Subcommittee of the NTP board of Scientific Counselors (October 1997).

NTP (National Toxicology Program), 1999. 9th NTP report on carcinogens – document on Saccharin (Appendix B).

OECD (Organisation for Economic Co-operation and Development), 1997. Test no. 471: bacterial reverse mutation test. In: OECD guidelines for the testing of chemicals, Section 4: Health effects, 11 pp.

OECD (Organisation for Economic Co-operation and Development), 1998. OECD principles on good laboratory practice, OECD series on principles of good laboratory practice and compliance monitoring, no. 1. OECD Publishing, Paris. https://doi.org/10.1787/9789264078536-en

OECD (Organisation for Economic Co-operation and Development), 2016. Test no. 487: in vitro mammalian cell micronucleus test, OECD guidelines for the testing of chemicals, section 4. OECD Publishing, Paris. https://doi.org/10.1787/9789264264861-en

OECD (Organisation for Economic Co-operation and Development), 2018. Test no. 408: repeated dose 90-day oral toxicity study in rodents, OECD guidelines for the testing of chemicals, section 4. OECD Publishing, Paris. https://doi.org/10.1787/9789264070707-en

Parschat K, Melsaether C, Jäpel K and Jennewein S, 2021. Clinical evaluation of 16-week supplementation with 5HMO-mix in healthy-term infants to determine tolerability, safety, and effect on growth. Nutrients, 13, 2871. https://doi.org/10.3390/nu13082871

Parschat K, Oehme A, Leuschner J, Jennewein S and Parkot J, 2020. A safety evaluation of mixed human milk oligosaccharides in rats. Food and Chemical Toxicology, 136, 111118.

Radke M, Picaud JC, Loui A, Cambonie G, Faas D, Lakefèr HN, de Groot N, Pecquet SS, Steenhout PG and Hascoet JM, 2017. Starter formula enriched in prebiotics and probiotics ensures normal growth of infants and promotes gut health: a randomized clinical trial. Pediatric Research, 81, 622–631.

Rijnerse A, Jeurink PV, van Esch BCAM, Garssen J and Knippels LMJ, 2011. Food-derived oligosaccharides exhibit pharmaceutical properties. European Journal of Pharmacology, 668, S117–S123.

Röhrig CH, Choi SSH and Baldwin N, 2017. The nutritional role of free sialic acid, a human milk monosaccharide, and its application as a functional food ingredient. Critical Reviews in Food Science and Nutrition, 57, 1017–1038.

Rudloff S and Kunz C, 2012. Milk oligosaccharides and metabolism in infants. American Society for Nutrition. Advances in Nutrition, 3, 398 S–405 S.

Rudloff S, Obermeier S, Borsch C, Pohlentz G, Hartmann R, Brösicke H, Lentze MJ and Kunz C, 2006. Incorporation of orally applied (13)C-galactose into milk lactose and oligosaccharides. Glycobiology, 16, 477–487.

Rudloff S, Pohlentz G, Diekmann L, Egge H and Kunz C, 1996. Urinary excretion of lactose and oligosaccharides in preterm infants fed human milk or infant formula. Acta Paediatrica, 1996, 598–603.

Samuel TM, Binia A, de Castro CA, Thakkar SK, Billeaud C, Agosti M, Al-Jashi I, Costeira MJ, Marchini G, Martinez-Costa C, Picaud JC, Stiris T, Stoicescu SM, Vanpee M, Domellöf M, Austin S and Sprenger N, 2019. Impact of maternal characteristics on human milk oligosaccharide composition over the first 4 months of lactation in a cohort of healthy European mothers. Scientific Reports, 9, 11767.

Simeoni U, Berger B, Junick J, Blaut M, Pecquet S, Rezzonico E, Grathwohl D, Sprenger N, Brüssow H, Team S, Szajewska H, Bartoli JM, Brevaut-Malaty V, Borszewska-Kornacka M, Feleszko W, François P, Gire C, Leclaire M, Maurin JM, Schmidt S, Skórka A, Squizaro C and Verdott JH, 2016. Gut microbiota analysis reveals a marked shift to bifidobacteria by a starter infant formula containing a symbiotic of bovine milk-derived oligosaccharides and Bifidobacterium animalis subsp. lactis CNCM I-3446. Environmental Microbiology, 18, 2185–2195.

Spevecak AR, Smilowitz JT, Chin EL, Underwood MA, German JB and Slupsky CM, 2015. Infant mortality at birth reveals minor differences in the maternal milk metabolome in the first month of lactation. Journal of Nutrition, 145, 1698–1708.

Soyunilmaz B, Mikes MH, Röhrig CH, Matwiejuk M, Meszaros-Matwiejuk A and Vignaes LK, 2021. The mean of milk: a review of human milk oligosaccharide concentrations throughout lactation. Nutrients, 13, 2737.

Tarr AJ, Galley JD, Fisher S, Chichlowski M, Berg BM and Bailey MT, 2015. The prebiotics 3′-Sialyllactose and 6′-Sialylactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: evidence for effects on the gut-brain axis. Brain, Behavior, and Immunity, 50, 166–177.

Thurl S, Munzert M, Henker J, Boehm G, Muller-Werner B, Jelinek J and Stahl B, 2010. Variation of human milk oligosaccharides in relation to milk groups and lactational periods. British Journal of Nutrition, 104, 1261–1271.

Thurl S, Munzert M, Boehm G, Matthews C and Stahl B, 2017. Systematic review of the concentrations of oligosaccharides in human milk. Nutrition Reviews, 75, 920–933.

Urashima T, Taurik E, Fukuda K and Asakuma S, 2013. Recent advances in studies on milk oligosaccharides of cows and other domestic farm animals. Bioscience, Biotechnology, and Biochemistry, 77, 455–466.

Urashima T, Yamaguchi E, Ohshima T, Fukuda K and Saito T, 2018. Chemical structures of oligosaccharides in milk of the raccoon (Procyon lotor). Glycoconjugate Journal, 35, 275–286.
USFDA, 2019. No GRN. 766 [3′-SL sodium salt; GeneChem Inc., Daejeon, Republic of Korea]. In: GRAS Notices. US Food and Drug Administration (US FDA), Center for Food Safety & Applied Nutrition (CFSAN), Office of Food Additive Safety, Silver Spring (MD). Available online: https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices&id=766&sort=GRN_No&order=DESC&startrow=1&type=GRN&search=766

USFDA, 2020a. No GRN. 880 [3′-SL sodium salt; Glycom A/S, Hørsholm, Denmark]. In: GRAS Notices. US Food and Drug Administration (US FDA), Center for Food Safety & Applied Nutrition (CFSAN), Office of Food Additive Safety, Silver Spring (MD). Available online: https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices&id=880&sort=GRN_No&order=DESC&startrow=1&type=GRN&search=880

USFDA, 2020b. No GRN. 881 [6′-SL sodium salt; Glycom A/S, Hørsholm, Denmark]. In: GRAS Notices. US Food and Drug Administration (US FDA), Center for Food Safety & Applied Nutrition (CFSAN), Office of Food Additive Safety, Silver Spring (MD). Available online: https://www.cfsanappsexternal.fda.gov/scripts/fdcc/?set=GRASNotices&id=881&sort=GRN_No&order=DESC&startrow=1&type=GRN&search=881

Zeng J, Hu Y, Jia T, Zhang R, Su T, Sun J, Gao J, Li G, Cao M and Song M, 2018. Chemoenzymatic synthesis of sialylated lactuloses and their inhibitory effects on Staphylococcus aureus. PLoS One, 13, e0199334.

### Abbreviations

1D Mono-dimensional  
2D Two-dimensional  
2′-FL 2′-Fucosyllactose  
3-FL 3-Fucosyllactose  
3′-SL 3′-Sialyllactose  
6′-SL 6′-Sialyllactose  
ADME Absorption, Distribution, Metabolism and Excretion  
AI Adequate intake  
ASU Official collection of analysis methods according to § 64 of the German Food and Feed Code (LFGB)  
bw Body weight  
CAS Chemical Abstracts Service  
CFU Colony forming unit  
CID Collision induced dissociation  
COSY Correlated spectroscopy  
CrI:CD(SD) rats Charles River Laboratories: Caesarean-derived (Sprague Dawley) rats  
DEPT Distortionless enhancement by polarisation transfer  
DFL Difucosyllactose  
DIN German Institute for Standardisation e. V.  
DM Dry matter  
DNA Deoxyribonucleic Acid  
DSMZ German Collection of Microorganisms and Cell Cultures  
EC European Commission  
EN European norm  
EU Endotoxin unit  
EU European Union  
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed  
FOF Follow-on formulae  
FoodEx2 EFSA standardised food classification and description system  
FSSC 22000 Food Safety System Certification 22000  
Gal Galactose  
Glc Glucose  
GLP Good Laboratory Practices  
GMO EFSA Panel on Genetically Modified Organisms  
GMP Good Manufacturing Practice  
GRAS Generally Recognised As Safe  
GRN GRAS Notice  
HACCP Hazard Analysis Critical Control Points  
HIOM Human-identical milk oligosaccharide  
HMBC Heteronuclear multiple-bond correlation  
HMO Human milk oligosaccharide
| Acronym | Full Form |
|---------|-----------|
| HPAEC-PAD | High-performance anion-exchange chromatography – pulsed amperometric detection |
| HPLC-ESI | High-performance liquid chromatography – electrospray ionisation |
| HSQC | Heteronuclear single quantum correlation |
| IAC-HPLC-FD | Immunoaffinity chromatography – high-performance liquid chromatography – fluorescence detector |
| IARC | International Agency for Research on Cancer |
| ICP-MS | Inductively coupled plasma – mass spectrometry spectrometry |
| IF | Infant formulae |
| ISO | International Organisation for Standardisation |
| IUPAC | International Union of Pure and Applied Chemistry |
| LFGB | German Food and Feed Code |
| LNNt | Lacto-N-neotetraose |
| LNT | Lacto-N-tetraose |
| LOQ | Limit of quantification |
| MRM | Multiple reaction monitoring |
| MS | Mass spectrometry |
| MS/MS | Tandem mass spectrometry |
| NANA, Neu5A | N-acetyl-D-neuraminic acid |
| ND | Not detected |
| NDA | EFSA Panel on Nutrition, Novel Foods and Food Allergens |
| NF | Novel food |
| NMR | Nuclear magnetic resonance spectroscopy |
| NOAEL | No observed adverse effect level |
| NTP | US National Toxicology Program |
| OECD | Organisation for Economic Co-operation and Development |
| Ph. Eur. | European Pharmacopoeia |
| qPCR | Quantitative polymerase chain reaction |
| RH | Relative humidity |
| RNA | Ribonucleic acid |
| SD rats | Sprague Dawley rats |
| TG | Test guidelines |
| TOCSY | Total correlation spectroscopy |
| TS | Technical specification |
| US FDA | US Food and Drug Administration |
| US | United States |
| w/w | weight per weight |
## Appendix A – Authorised and proposed uses and use levels for 6′-SL

| Specified food category | Maximum use levels | Authorised\(^{(a)}\) | Proposed |
|-------------------------|---------------------|------------------------|----------|
| Unflavoured pasteurised and unflavoured sterilised (including UHT) milk products | | 0.5 g/L | – |
| Unflavoured fermented milk-based products | | 0.5 g/L beverages 2.5 g/kg non bev. | – |
| Flavoured fermented milk-based products including heat-treated products | | 0.5 g/L beverages 5 g/kg non bev. | – |
| Beverages (flavoured drinks, excluding drinks with a pH less than 5) | | 0.5 g/L | – |
| Cereal bars | | 5 g/kg | – |
| Infant formula as defined in Regulation (EU) No 609/2013 | | 0.4 g/L | 0.7 g/L |
| Follow-on formula as defined in Regulation (EU) No 609/2013 | | 0.3 g/L | 0.7 g/L |
| Processed cereal-based food and baby food for infants and young children as defined in Regulation (EU) No 609/2013 | | 0.3 g/L beverages 2.5 g/kg non bev. | 0.7 g/L |
| Milk-based drinks and similar products intended for young children | | 0.3 g/L | 0.7 g/L |
| Total diet replacement foods for weight control as defined under Regulation (EU) No 609/2013 | | 1 g/L beverages 10 g/kg non bev. | – |
| Food for special medical purposes as defined under Regulation (EU) No 609/2013 | | In accordance with the particular nutritional requirements of the persons for whom the products are intended |
| Food supplements | | 1 g/day\(^{(b)}\) | 1.8 g/day infants and young children |

\(^{(a)}\): As included in the Union list (Regulation (EU) 2017/2470).
\(^{(b)}\): Excluding food supplements for infants and young children.
Annex A – Dietary exposure estimates to the Novel Food for each population group from each EU dietary survey

Information provided in this Annex is shown in an Excel file (downloadable at https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2022.7645#support-information-section).